Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 263

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Long-term benefits and adverse effects of intermittent versus daily glucocorticoids in boys with Duchenne muscular dystrophy

Open access
Ricotti, V., Ridout, D. A., Scott, E., Quinlivan, R., Robb, S. A., Manzur, A. Y., Muntoni, F., on behalf of the NorthStar Clinical Network, Manzur, A., Muntoni, F., Robb, S., Quinlivan, R., Ricotti, V., Main, M., Dubowitz Neuromuscular Centre, Great Ormond Street Hospital for Children NHS Trust, London, Bushby, K., Straub, V., Sarkozy, A., Guglieri, M., Strehle, E., Eagle, M., Mayhew, A., Roper, H., McMurchie, H., Childs, A., Pysden, K., Pallant, L., Spinty, S., Peachey, G., Shillington, A., Wraige, E., Jungbluth, H., Sheehan, J., Spahr, R., Hughes, I., Bateman, E., Cammiss, C., Willis, T., Groves, L., Emery, N., Baxter, P., Senior, M., Hartley, L., Parsons, B., Majumdar, A., Jenkins, L., Naismith, K., Keddie, A., Horrocks, I., Di Marco, M., Chow, G., Miah, A., de Goede, C., Thomas, N., Geary, M., Palmer, J., White, C., Greenfield, K., Scott, E.·2013·Journal of Neurology, Neurosurgery & Psychiatry

Abstract

OBJECTIVE: To assess the current use of glucocorticoids (GCs) in Duchenne muscular dystrophy in the UK, and compare the benefits and the adverse events of daily versus intermittent prednisolone regimens. DESIGN: A prospective longitudinal observational study across 17 neuromuscular centres in the UK of 360 boys aged 3-15 years with confirmed Duchenne muscular dystrophy who were treated with daily or intermittent (10 days on/10 days off) prednisolone for a mean duration of treatment of 4 years. RESULTS: The median loss of ambulation was 12 years in intermittent and 14.5 years in daily treatment; the HR for intermittent treatment was 1.57 (95% CI 0.87 to 2.82). A fitted multilevel model comparing the intermittent and daily regiments for the NorthStar Ambulatory Assessment demonstrated a divergence after 7 years of age, with boys on an intermittent regimen declining faster (p<0.001). Moderate to severe side effects were more commonly reported and observed in the daily regimen, including Cushingoid features, adverse behavioural events and hypertension. Body mass index mean z score was higher in the daily regimen (1.99, 95% CI 1.79 to 2.19) than in the intermittent regimen (1.51, 95% CI 1.27 to 1.75). Height restriction was more severe in the daily regimen (mean z score -1.77, 95% CI -1.79 to -2.19) than in the intermittent regimen (mean z score -0.70, 95% CI -0.90 to -0.49). CONCLUSIONS: Our study provides a framework for providing information to patients with Duchenne muscular dystrophy and their families when introducing GC therapy. The study also highlights the importance of collecting longitudinal natural history data on patients treated according to standardised protocols, and clearly identifies the benefits and the side-effect profile of two treatment regimens, which will help with informed choices and implementation of targeted surveillance.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/jnnp-2012-303902

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 36 references

Cited by

See all 263

Metadata

Authors
Ricotti, V., Ridout, D. A., Scott, E., Quinlivan, R., Robb, S. A., Manzur, A. Y., Muntoni, F., on behalf of the NorthStar Clinical Network, Manzur, A., Muntoni, F., Robb, S., Quinlivan, R., Ricotti, V., Main, M., Dubowitz Neuromuscular Centre, G. O. S. H. F. C. N. T., Bushby, K., Straub, V., Sarkozy, A., Guglieri, M., Strehle, E., Eagle, M., Mayhew, A., Roper, H., McMurchie, H., Childs, A., Pysden, K., Pallant, L., Spinty, S., Peachey, G., Shillington, A., Wraige, E., Jungbluth, H., Sheehan, J., Spahr, R., Hughes, I., Bateman, E., Cammiss, C., Willis, T., Groves, L., Emery, N., Baxter, P., Senior, M., Hartley, L., Parsons, B., Majumdar, A., Jenkins, L., Naismith, K., Keddie, A., Horrocks, I., Di Marco, M., Chow, G., Miah, A., de Goede, C., Thomas, N., Geary, M., Palmer, J., White, C., Greenfield, K., & Scott, E.
Venue
Journal of Neurology, Neurosurgery & Psychiatry
Publisher
BMJ
Published
2012-12-18
Volume
84
Issue
6
Pages
698-705
ISSN
0022-3050 (ISSN-L)
OpenAlex
W2113949094
Cited by
263
References
36
FWCI
7.20
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Long-term benefits and adverse effects of intermittent versus daily glucocorticoids in boys with Duchenne muscular dystrophy. https://app.cochat.ai/papers/10.1136/jnnp-2012-303902
The paper
Ricotti, V., Ridout, D. A., Scott, E., Quinlivan, R., Robb, S. A., Manzur, A. Y., Muntoni, F., on behalf of the NorthStar Clinical Network, Manzur, A., Muntoni, F., Robb, S., Quinlivan, R., Ricotti, V., Main, M., Dubowitz Neuromuscular Centre, G. O. S. H. F. C. N. T., Bushby, K., Straub, V., Sarkozy, A., Guglieri, M., . . . Scott, E. (2013). Long-term benefits and adverse effects of intermittent versus daily glucocorticoids in boys with Duchenne muscular dystrophy. Journal of Neurology, Neurosurgery & Psychiatry. https://doi.org/10.1136/jnnp-2012-303902

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.